About
Peter qualified in medicine at Westminster Medical School. Having first worked as a physician at The Whittington Hospital and KCH, he trained in psychiatry at the Maudsley Hospital and epidemiology at the London School of Hygiene. He has been Professor of Psychiatry at Cambridge since 2000, Head of Department of Psychiatry from 2000-2014, and Deputy Head of the Clinical School since 2014. He has been a NIHR CLARHC Director since 2008 and is a NIHR Senior Investigator. Peter’s research interests are in the epidemiology of mental illness, particularly early life determinants, and in evaluation of effective interventions at the individual and system level. Clinically he co-led the award winning CAMEO.nhs.uk early intervention service until taking on his NIHR responsibilities in the Collaboration for Leadership in Applied Health Research & Care East of England. Peter studied medicine at KCL and Westminster Medical School. He practised hospital medicine for three years before tasting psychiatry at the Maudsley Hospital and Institute of Psychiatry where he remained for nine years becoming an honorary consultant and senior lecturer; three of these were spent as an MRC Training Fellow and reading Epidemiology at the London School of Hygiene and Tropical Medicine. He was seconded half-time to the Department of Health 1993-1996 where he led the Policy Research Programme Mental Health Research Initiative and convened the multi-party group that led to the reduction in paracetamol pack size as part of the national suicide prevention policy. After five years at the University of Nottingham, four as Professor of Psychiatry and Community Mental Health, Peter moved to Cambridge in 2000 as Head of Department of Psychiatry and honorary consultant psychiatrist with the Cambridgeshire & Peterborough NHS Foundation Trust.; he was co-founder of the award-winning Cameo early intervention team for young people who experience a first episode of psychosis. In 2014 he stepped-down as Head of Department to become Deputy Head of the School of Clinical Medicine. Peter was elected a Fellow of Wolfson College in 2003. He is a Director of Cambridge University Health Partners, and Director of the National Institute of Health Research (NIHR) Collaboration for Leadership in Applied Health Research & Care for the East of England (CLAHRC EoE). He is a trustee of MQ: transforming mental health, a research charity endowed by the Wellcome Trust, and is an NIHR Senior Investigator Emeritus. Peter has been President of IEPA Early Intervention in Mental Health 2016-2018.
View more >>Skills
Experience
Senior Lecturer & honorary consultant psychiatrist
Institute of Psychiatry, Psychology & Neuroscience (IoPPN)
Sep-1991 to Sep-1995Honorary consultant psychiatrist
Cambridgeshire and Peterborough NHS Foundation Trust (CPFT)
Oct-2000 to Dec-2024Education
Publication
Ten-year outcomes in first episode psychotic major depression patients compared with schizophrenia and bipolar patients
We aimed to investigate long-term outcomes in psychotic major depression patients compared to schizophrenia and bipolar/manic psychosis patients, in an incidence sample, while accounting for...
Body mass index in the middle-aged offspring of parents with severe mental illness
Background People with severe mental illness (SMI) have an elevated risk of obesity but the causes and mechanisms are unclear. We explored the familial association between parental SMI and ...
Sexually divergent development of depression-related brain networks during healthy human adolescence
Sexual differences in human brain development could be relevant to sex differences in the incidence of depression during adolescence. We tested for sex differences in parameters of normative...
Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and c...
Background First episode psychosis (FEP) patients who use cannabis experience more frequent psychotic and euphoric intoxication experiences compared to controls. It is not clear whether thi...
Preference uncertainty accounts for developmental effects on susceptibility to peer influence in adolescence
Adolescents are prone to social influence from peers, with implications for development, both adaptive and maladaptive. Here, using a computer-based paradigm, we replicate a cross-sectional ...
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study
Background Daily use of high-potency cannabis has been reported to carry a high risk for developing a psychotic disorder. However, the evidence is mixed on whether any pattern of cannabis u...
Neurological Signs at the First Psychotic Episode as Correlates of Long-Term Outcome: Results From the AESOP-10 Study
Minor neurological signs are subtle deficits in sensory integration, motor coordination, and sequencing of complex motor acts present in excess in the early stages of psychosis. Still, it re...
Advancing methodology for scoping reviews: recommendations arising from a scoping literature review (SLR) to inform transformation of Children and Ado...
Background There is consensus that health services commissioning and clinical practice should be driven by scientific evidence. However, workload pressures, accessibility of peer reviewed p...
Reinforcement learning as an intermediate phenotype in psychosis? Deficits sensitive to illness stage but not associated with polygenic risk of schizo...
Background Schizophrenia is a complex disorder in which the causal relations between risk genes and observed clinical symptoms are not well understood and the explanatory gap is too wide to...
Schizotypy-Related Magnetization of Cortex in Healthy Adolescence Is Colocated With Expression of Schizophrenia-Related Genes
Background Genetic risk is thought to drive clinical variation on a spectrum of schizophrenia-like traits, but the underlying changes in brain structure that mechanistically link genomic va...
Projects
Early Psychosis Multi-arm Multi-stage Platform Trial (PUMA)
Funded by Wellcome (London, GB)
Cogs AI - Social - Emotional Screener for Neurodiverse Children
Funded by Innovate UK (Swindon, GB)
Market research for Cambridge Adaptive Testing Ltd.
Funded by University of Cambridge
Access to Expertise for Cambridge Adaptive Testing - Mental health screening platforms – medical d...
Funded by Wellcome Trust (London, GB)
Conference/Seminar/STTP/FDP/Symposium/Workshop
- Dec 2018
Predicting Population-level Need for Early Treatment Programmes in First Episode Psychosis: The Advanced Psychiatric MAPping Translated into Innovations for Care [PsyMaptic-A] Study
Wiley ,
Hoboken, New Jersey, United StatesMembership
Trustee
Mental Health Research UK
From year 2019 to PresentEmeritus Professor of Psychiatry
University of Cambridge
From year 2021 to PresentPatent
- Medical & Health Science
Model directed sampling system
SYSTEMS & TECHNOLOGY RESEARCH LLC System & Technology Research LLC
United States
Mar 2016
15/059,838
US20160259844A1
Published
Sep 2016
- Medical & Health Science
Systems and Methods for Managing Documents and Other Electronic Content
Intertrust Technologies Corp
United States
Mar 2014
US14/229,650
US20140298207A1
Published
Oct 2014
- Medical & Health Science
Matched mailer form
Moore Business Forms Inc
United States
Dec 1992
US07/835,481
US5174491A
Published
Dec 1992
Scholar9 Profile ID
S9-122024-2107446
Publication
(221)
Article Reviewed
(0)
Citations
(131)
Network
(12)
Conferences/Seminar
(1)